CUDC-101

DB12174InvestigationalSmall molecule

CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.

Mechanism: Pharmacologically active on Receptor tyrosine-protein kinase erbB-2, Histone deacetylase, and Epidermal growth factor receptor
Curator reviewed
Formula / weight: C₂₄H₂₆N₄O₄ · 434.496 g/mol (avg)
Code names: CUDC-101

Resolves to

Compound

Structure

InChIKeyPLIVFNIUGLLCEK-UHFFFAOYSA-NSMILESCOC1=C(OCCCCCCC(=O)NO)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

424Drug interactionsStructured to mechanism, not free text

4Clinical trialsPhase, status and sponsor resolved per trial

12+ReferencesStructured and connected to the statements they support

Which drugs share a target with CUDC-101, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.